Objective: The purpose of this study was to investigate urinary continence four weeks following Retzius-sparing robotassisted radical prostatectomy. Patients and methods: Forty patients with T2-T3 prostate cancer underwent Retzius-sparing-robot-assisted radical prostatectomy and their results were compared with those from the 40 patients having robot-assisted radical prostatectomy done by the same surgeon immediately prior to the adoption of Retzius-sparing-robot-assisted radical prostatectomy. Results: Patients in the two groups had similar age, body mass index, prostate specific antigen, biopsy Gleason sum, clinical stage, d'Amico risk profile, blood loss, prostate weight and post-operative hospital stay. Median operating time (200 (interquartile range=155-266) vs 223 (interquartile range=100-238) min; p=0.05) and catheterisation (8 (interquartile range=8-8) vs 14 (interquartile range=14-14) days; p<0.0001) were shorter in the Retzius-sparing group, many of whom had suprapubic catheters inserted. The overall complication rate was lower in Retzius-sparing patients (2.5% vs 8.0%; p=0.36). Positive surgical margin rates were similar for Retzius-sparing and non-Retzius-sparing patients and decreased with greater experience with the Retzius-sparing technique: 16.7% vs 7.7% for pT2 (p=0.65) and 31.8% vs 14.3% for pT3 (p=0.44). Initial prostate specific antigen was <0.1 ng/ml in 97.5% and 100%, respectively (p=1.00). At four weeks post-operation 0, 1 and 2 pads/day were needed in the Retzius-sparing group in 90.0%, 7.5% and 2.5% of patients, compared to 37.5% (p<0.0001), 32.5% (p=0.01) and 30% (p=0.002) of men having conventional surgery. Conclusion: Retzius-sparing-robot-assisted radical prostatectomy is faster than the anterior approach to the prostate, allows a shorter catheterisation time and produces dramatically better continence results at four weeks with 90% of patients being pad-free and 97.5% of patients needing 0-1 pads/day.
Introduction
Radical prostatectomy (RP) is the only treatment modality for localised prostate cancer that has been shown in a randomised controlled trial to improve prostate cancerspecific mortality. 1 It is also the only modality which provides a definitive grade and stage following treatment, certainty of treatment efficacy during follow-up, and which preserves the other two main therapeutic options for later use as salvage therapy if needed. However, RP also has the potential to negatively impact a patient's quality of life 2 by producing stress urinary incontinence (SUI) and erectile dysfunction, with up to 35% of men needing to use incontinence pads 3 and 89% of patients reporting impotence one year after surgery. 4 Of these two undesirable consequences of surgery it appears that the persistence of post-prostatectomy SUI (PPSUI) lowers quality of life scores most. 5 A variety of techniques have been described to reconstruct the peri-prostatic structures that are disturbed during RP, in order to improve PPSUI. A cumulative analysis of 12 evaluable series by Rocco and colleagues demonstrated that some form of reconstruction improved continence rates at 3-7 days and at 30-45 days after catheter removal, but no longer made a difference by 90 days following catheter removal. 6 Tewari and colleagues reported that both anterior reconstruction and total anatomic restoration significantly improved continence throughout the first year after surgery. 7 However, it would be more preferable to not disturb the structures that required subsequent reconstruction at all, if this were feasible.
The early experience of robotic Retzius-sparing radical prostatectomy has yielded excellent early continence results in experienced hands with pad-free rates within a month of RARP of 90-92% 8 and 92%, 9 compared to 7-53.2% for non-RS RARP. 10, 11 In theory, this approach might also improve potency rates as it would allow preservation of any accessory pudendal arteries present as well as the arteries that travel in the dorsal vascular complex (DVC), both of which contribute towards the arterial inflow into the corpora cavernosa and therefore potency.
This study investigates the results of Retzius-sparing robot-assisted radical prostatectomy (RS-RARP) in the hands of a single surgeon who had recently adopted RARP but who already had considerable experience of performing laparoscopic RP.
Materials and methods
Forty men with cT2-T3 prostate cancer who had chosen surgical treatment over other options underwent RS-RARP. The series was consecutive. There were no exclusions in the first 15 patients but following this, patients with prostates >80 ml and/or having salvage RP were excluded from the RS approach for the reasons given below. All patients had a multiparametric magnetic resonance imaging (MRI) scan prior to surgery in addition to an isotope bone scan or a whole body bone marrow MRI scan if indicated by their cancer parameters.
As previously described by Bocciardi 8 and Rha 9 the peritoneum overlying the vasa and seminal vesicles (SVs) was incised in a shallow inverted 'U' shape (using a 30° down laparoscope) and the seminal vesicles and vasa were dissected. Diathermy was avoided and metallic clips were used to control SV arteries if nerve preservation was to be performed on that side. The peritoneum was then suspended from the anterior abdominal wall either side of the midline using two 2/0 nylon sutures mounted on a straight needle. The laparoscope was then changed to 30° up before the posterior plane between the rectum and prostate was developed: inside Denonviller's fascia for d'Amico low-risk patients and outside it for higher risk patients. Lateral pedicles and vessels passing from the neurovascular bundles (NVBs) to the prostate were controlled with clips. NVBs were either fully-preserved, partially-preserved or excised depending on the stage and grade of disease on that side. The dissection was continued anteriorly alongside the lateral aspect of the prostate on each side. The bladder neck was divided and the DVC was separated from the anterior aspect of the prostate with diathermy. The apex of the prostate was then dissected and the urethra divided. Following haemostasis, the anastomosis was done starting at the anterior midline using two continuous 2/0 Quill barbed sutures, which were then tied in the posterior midline using a 16F catheter as a guide. In the latter part of the series the bladder was then filled with 400 ml of saline before a 16-Fr suprapubic catheter (SPC) was inserted and the urethral catheter removed. In patients with a ≥5% risk of lymph node involvement according to the Briganti nomogram an extended pelvic lymphadenectomy (ePLND) was done. The midline peritoneal incision was closed with a continuous 3/0 Vicryl suture. Either one (posterior to the bladder) or three (posterior to the bladder and on either side of the pelvis) 10-Fr low-pressure suction drains were placed at the end of the procedure, depending on whether an ePLND had been done.
Venous thromboembolism (VTE) prophylaxis took the form of pneumatic intermittent calf compression during surgery, subcutaneous heparin commencing the morning following surgery, calf compression stockings and early ambulation. Oral fluids and a diet were introduced as tolerated. Drains were removed when drainage was <100 ml/24 h. Patients were discharged home when comfortable. Catheters were removed at 8-14 days, according to local protocols and after the SPC (if used) had been clamped for 24 h without a prior cystogram. Operating time was from the first skin incision to closure of the last skin incision. Complications and pad usage were patient-reported and were captured and recorded at clinic visits, the first of which was at four weeks after surgery. The results of the 40 patients having RS-RARP were compared with those from the 40 patients having RARP done by the same surgeon immediately prior to the adoption of RS-RARP using a conventional antegrade technique.
Data was prospectively recorded using Microsoft Access software (Microsoft Corporation, Redmond, USA) and analysed using Microsoft Excel 2016 and Analyse-it version 2.20 software (Analyse-it Software Ltd, Leeds, England). Continuous variables were compared using the independent samples t-test and rates using Fisher's exact test. Statistical significance was defined as p≤0.05. This study satisfies all Martin-Donat criteria. 12 
Results
Patient demographics are summarised in Table 1, inpatient  results in Table 2 , complications in Table 3 and post-operative results in Table 4 . Patients in the two groups had a similar age (p=0.15), body mass index (BMI) (p=0.68), prostate specific antigen (PSA) (p=0.46), biopsy Gleason sum (p=0.28), clinical stage (p=0.65-1.00), d'Amico risk profile (p=0.65-1.00), blood loss (0.95), prostate weight (p=0.67) and post-operative hospital stay (p=1.00). Eight patients in the RARP group had previously undergone abdominal surgery, including appendisectomy (n=3), bilateral laparoscopic total extraperitoneal (TEP) mesh hernia repair (n=1), sigmoid colectomy (n=1) and ileostomy with low anterior resection of the rectum (n=1). Previous surgery in the RS-RARP group included urethrotomy (n=1), open inguinal hernia repair (n=1), a Whipple operation (n=1) and a patient whose laparoscopic RP had been abandoned by a surgeon at another institution as he had been unable to dissect below the mesh placed at his previous laparoscopic bilateral TEP hernia repair.
There were no conversions to open surgery but three of the first 15 cases in the RS-RARP group were converted to an anterior approach because of a failure to progress: this occurred in patients with an 18 ml prostate, a 98 ml prostate and a salvage case following previous high-intensity focused ultrasound (HIFU) hemi-ablation. There were no blood transfusions. The median operating time (200 (interquartile range (IQR)=155-266) vs 223 (IQR=100-238) min; p=0.05) and catheterisation (8 (IQR 8-8) vs 14 (IQR=14-14) days; p<0.0001) were shorter in the RS group -this was because a SPC, which was clamped after seven days and removed after eight days, was only used in RS-RARP cases (Table 2) .
Although the overall complication rate was lower in RS patients (2.5% vs 8.0%; p=0.36), this included the most serious complication of the series (obstruction of the left ureter by a clip) and occurred in the fifth RS-RARP case ( Table 3 ). The patient presented with flank pain and was initially managed by nephrostomy insertion. Attempts to pass a guide-wire antegrade and retrograde both failed and the left ureter was implanted robotically with no sequelae. The RARP patient who had an infected pelvic collection presented with sepsis almost three weeks after surgery and was managed successfully by percutaneous drain insertion and antibiotics.
Positive surgical margin (PSM) rates were similar for RS and non-RS patients and decreased with greater experience with the RS technique: 16.7% vs 7.7% for pT2 (p=0.65) and 31.8% vs 14.3% for pT3 (p=0.44), respectively (Table 4 ). The location of PSMs was similar in the two groups and in particular the anterior PSM was not significantly higher in RS-RARP cases (5.0% vs 0.0%; p=0.49). The initial PSA was <0.1 ng/ml in all RARP patients and all but one RS-RARP case (97.5%, p=1.00), 24% of whose 31 g prostate was replaced by margin-positive Gleason 5+4 pT3aN1 (1/33 nodes) prostate cancer.
At their initial post-operative clinic visit, four weeks following surgery, the percentage of patients using 0, 1 and 2 pads/day in the RS-RARP group was 90.0%, 7.5% and 2.5%, respectively, compared to 37.5% (p<0.0001), 32.5% (p=0.01) and 30.0% (p=0.002) after RARP ( Figure 1 ).
Discussion
Consistent with the findings of Lim and colleagues in their initial 50 cases, 9 this study demonstrated a lower operating time after RS-RARP compared to conventional surgery. This is logical, as several operative steps that are necessary to perform during the anterior approach are omitted when doing RS-RARP: mobilisation of the bladder from the anterior abdominal wall, de-fatting of the prostate, bilateral incision of the endopelvic fascia, division of the puboprostatic ligaments, ligation and division of the DVC and any reconstructive technique that the surgeon favours, such as placement of a Rocco suture. It is reasonably expected that, as further experience with the RS technique is accrued, this operating time will fall further. Insertion of a SPC following RS-RARP proved to be as popular with this cohort of RARP patients as it was with their previous counterparts 13, 14 and, because it allowed a trial of voiding to be done at home, it also resulted in a shorter median duration of catheterisation. The technical difficulty of working in a confined space at the very depths of the male pelvis, especially in overweight and obese patients, together with the unconventional arrangement of the anatomy (the prostate is below than the bladder, in contrast to the usual situation in conventional RP) and the paucity of landmarks also noted by other workers 15 resulted in three conversions to an anterior approach in the first 15 patients. These cases were completed without any further difficulty. The authors were keen to assess the limits of RS-RARP at the start of their experience but now accept that large prostates (>80 ml) and especially those with prominent middle lobes, together with salvage cases would be better reserved for a time when greater experience and expertise have been gained. Confirming the authors' perception, Rha and colleagues have recently reported higher transfusion rates in prostates >60 ml; there was also a trend to more complications and operation time. It is also noteworthy that none of the 294 patients analysed from this centre had a prostate volume >85 ml. 16 The difficulty in identifying and safeguarding the ureters during RS-RARP was highlighted by the case of ureteric injury in the fifth case in the series. This patient had cT3a disease on the left and wide excision of the left NVB was done. Greater experience and use of peritoneal suspension sutures will hopefully reduce the probability of ureteric injury in the future, but it is certainly disconcerting for the surgeons operating not to be able to see into the bladder to identify (and, if necessary, stent intra-operatively) the ureteric orifices. RS-RARP also seems to be a logical approach to RP in men who have previously had laparoscopic mesh TEP hernia surgery, as exemplified by the 'salvage' case in this series, although the authors have never previously themselves failed to complete a non-RS RP in a man who has had a laparoscopic TEP mesh hernia repair. Although the higher PSM rate (31.8% vs 14.3%) for pT3 cases in the RS-RARP group compared to RARP patients was not statistically significant (p=0.15) and compares favourably with the pT3 PSM rate of 50% in the hands of surgeons with much greater experience of RS-RARP, 8 the ability to excise sufficient tissue around the prostate in high-risk cases in order to achieve a negative surgical margin (the radial margin was involved in all seven positive PSM cases in this series), whilst avoiding injury to the ureter, remains an area of potential concern to the authors, especially as high-risk prostate cancers comprise 40-50% of their typical annual case load of RPs. Further experience with this technique will clarify whether this is a reasonable approach for T3 patients or not. The authors were interested to note that the location of PSMs was similar in RS-RARP and RARP patients (p=0.72-1.00; Table 4 ).
The largest difference in results between the two groups was noted for continence. Specifically, at four weeks following surgery the pad-free rate was almost 3× higher following RS-RARP than after RARP and the proportion of patients using 0-1 pads/day at that time was 97.5%. The 90% pad-free rate four weeks after surgery is similar to the figure of 92% reported by Lim and colleagues in their first 50 cases of RS-RARP 9 and identical to that reported by Galfano and colleagues seven days following catheter removal in their second cohort of 100 operated patients. 8 The authors feel that the explanation for this is self-evident, namely the preservation of the structures that are known to support the external urinary sphincter, which include the DVC, puboprostatic ligaments and endopelvic fascia, together with vessels and nerves that supply and innervate the rhabdosphincter. Indeed, the ability to preserve the sometimes sizeable arteries that run in the DVC and any accessory pudendal arteries that are present constitute further potential advantages for the use of RS-RARP. Although evaluation of potency so soon after surgery would have been meaningless in this study, potency rates in these patients and future RS-RARP patients having RS-RARP are awaited with interest.
Limitations of this study include its small size and consecutive and non-randomised nature, which exposes it to risks of cohort and selection biases.
Conclusions
RS-RARP constitutes a faster, safe, reproducible and novel approach to RARP which produces dramatically better continence results at four weeks compared to non-RS RARP with a pad-free rate that is almost 3× higher and which allows 97.5% of patients to use 0-1 pads per day. The ability to safely use an SPC (as the bladder has not been dissected) also allows for a trial of voiding to be done at the patient's home, contributing to a shorter duration of catheterisation. 
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